Compare Stocks: INCR, NERV, CRDL, and SLGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.94 -5.8%	$1.35	$0.88 ▼ $2.28	$224.82M	0.72	1.51 million shs	1.66 million shs
INCR InterCure	$5.78 +1.8%	$4.96	$3.40 ▼ $8.45	$63.21M	1.4	40,219 shs	5,326 shs
NERV Minerva Neurosciences	$4.84 -5.7%	$4.53	$1.93 ▼ $12.46	$231.10M	-0.1	250,847 shs	135,733 shs
SLGL Sol-Gel Technologies	$68.81 -5.2%	$78.75	$21.10 ▼ $97.97	$193.35M	1.12	61,420 shs	147,789 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	0.00%	+4.30%	+59.67%	+59.02%	+73.21%
INCR InterCure	0.00%	+35.76%	+21.89%	-3.67%	-29.08%
NERV Minerva Neurosciences	0.00%	0.00%	+20.40%	-1.43%	+104.22%
SLGL Sol-Gel Technologies	0.00%	-11.48%	-19.23%	-6.84%	+213.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.94 -5.8%	$1.35	$0.88 ▼ $2.28	$224.82M	0.72	1.51 million shs	1.66 million shs
INCR InterCure	$5.78 +1.8%	$4.96	$3.40 ▼ $8.45	$63.21M	1.4	40,219 shs	5,326 shs
NERV Minerva Neurosciences	$4.84 -5.7%	$4.53	$1.93 ▼ $12.46	$231.10M	-0.1	250,847 shs	135,733 shs
SLGL Sol-Gel Technologies	$68.81 -5.2%	$78.75	$21.10 ▼ $97.97	$193.35M	1.12	61,420 shs	147,789 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	0.00%	+4.30%	+59.67%	+59.02%	+73.21%
INCR InterCure	0.00%	+35.76%	+21.89%	-3.67%	-29.08%
NERV Minerva Neurosciences	0.00%	0.00%	+20.40%	-1.43%	+104.22%
SLGL Sol-Gel Technologies	0.00%	-11.48%	-19.23%	-6.84%	+213.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	415.46% Upside
INCR InterCure	1.00	Sell	N/A	N/A
NERV Minerva Neurosciences	1.75	Reduce	$10.33	113.50% Upside
SLGL Sol-Gel Technologies	2.67	Moderate Buy	$197.50	187.02% Upside

Current Analyst Ratings Breakdown

Latest INCR, NERV, CRDL, and SLGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/20/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
7/14/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/9/2026	INCR InterCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	CRDL Cardiol Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	INCR InterCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	SLGL Sol-Gel Technologies	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$285.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
INCR InterCure	$78.47M	0.81	N/A	N/A	$10.53 per share	0.55
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.47) per share	N/A
SLGL Sol-Gel Technologies	$19.39M	9.97	N/A	N/A	$17.12 per share	4.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
INCR InterCure	-$10.37M	$0.03	192.67	N/A	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
SLGL Sol-Gel Technologies	-$6.13M	-$5.64	N/A	N/A	N/A	-910.14%	-44.05%	-36.96%	N/A

Latest INCR, NERV, CRDL, and SLGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	-$1.13	+$1.23	-$1.13	$0.08 million	$0.59 million
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDL Cardiol Therapeutics	N/A	5.55	5.55
INCR InterCure	0.20	1.48	0.97
NERV Minerva Neurosciences	N/A	20.15	20.14
SLGL Sol-Gel Technologies	N/A	10.37	10.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDL Cardiol Therapeutics	12.49%
INCR InterCure	8.34%
NERV Minerva Neurosciences	34.56%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
CRDL Cardiol Therapeutics	5.25%
INCR InterCure	0.24%
NERV Minerva Neurosciences	1.70%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDL Cardiol Therapeutics	20	115.89 million	109.80 million	Not Optionable
INCR InterCure	350	10.94 million	10.91 million	Optionable
NERV Minerva Neurosciences	9	47.75 million	46.94 million	Not Optionable
SLGL Sol-Gel Technologies	50	2.81 million	941,000	No Data

INCR, NERV, CRDL, and SLGL Headlines

Recent News About These Companies

Sol-Gel Technologies Ltd.: Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 20, 2026 | finanznachrichten.de

Sol-Gel Technologies (NASDAQ:SLGL) Posts Quarterly Earnings Results, Beats Expectations By $1.23 EPS

August 20, 2026 | marketbeat.com

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 20, 2026 | globenewswire.com

Sol-Gel Technologies (SLGL) Projected to Announce Quarterly Earnings on Friday

August 14, 2026 | marketbeat.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by Brokerages

August 12, 2026 | marketbeat.com

Sol-Gel Technologies Insider Trading Activity | NASDAQ:SLGL | Benzinga

July 23, 2026 | benzinga.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 229 Shares

July 11, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,460.88 in Stock

July 3, 2026 | insidertrades.com

Sol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho Securities

June 26, 2026 | theglobeandmail.com

Sol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering

May 30, 2026 | theglobeandmail.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

May 28, 2026 | zacks.com

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 28, 2026 | globenewswire.com

Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 1,500 Shares of Stock

May 15, 2026 | insidertrades.com

Sol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary Shares

March 23, 2026 | quiverquant.comQ

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

March 23, 2026 | globenewswire.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates

March 19, 2026 | zacks.com

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

March 19, 2026 | globenewswire.com

This Under-the-Radar Stock Has Surged 1,300% Over the Past Year

March 13, 2026 | finance.yahoo.com

Sol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last year

February 11, 2026 | finance.yahoo.com

Sol-Gel Technologies (SLGL) price target increased by 120.00% to 112.20

February 4, 2026 | msn.com

Opaleye Management Inc. Buys 1,151 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock

January 24, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INCR, NERV, CRDL, and SLGL Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

$1.94 -0.12 (-5.83%)

As of 08/28/2026 04:00 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

InterCure NASDAQ:INCR

$5.78 +0.10 (+1.76%)

As of 08/28/2026 04:00 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Minerva Neurosciences NASDAQ:NERV

$4.84 -0.29 (-5.65%)

As of 08/28/2026 04:00 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Sol-Gel Technologies NASDAQ:SLGL

$68.81 -3.76 (-5.18%)

As of 08/28/2026 04:00 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INCR, NERV, CRDL, and SLGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INCR, NERV, CRDL, and SLGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INCR, NERV, CRDL, and SLGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INCR, NERV, CRDL, and SLGL Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

InterCure NASDAQ:INCR

Minerva Neurosciences NASDAQ:NERV

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INCR, NERV, CRDL, and SLGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INCR, NERV, CRDL, and SLGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INCR, NERV, CRDL, and SLGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INCR, NERV, CRDL, and SLGL Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

InterCure NASDAQ:INCR

Minerva Neurosciences NASDAQ:NERV

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools